← Back

Wire · opportunities

FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharmacytimes.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA granted accelerated approval to neladalkib for adults with advanced ALK-positive non-small cell lung cancer previously treated with specific ALK inhibitors and platinum chemotherapy. The approval is based on durable response data from the ALKOVE-1 trial, with ongoing confirmatory studies required.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Biotech founders in lung cancer should start structuring their clinical plans around accelerated approvals that hinge on durable responses in targeted subpopulations. This approval opens a narrow but clear path to market that demands precise patient selection and ongoing safety vigilance.

◆ Coverage

2 sources · 17 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDAaccelerated-approvalALK-NSCLCtargeted-therapyclinical-trial